Mechanism & research context
Survodutide is a dual agonist targeting the glucagon and GLP-1 receptors, investigated in preclinical settings for its effects on hepatic lipid handling, energy expenditure and incretin signalling crosstalk. Supplied as lyophilized powder at ≥98% HPLC purity.
Use disclaimerFor Research Use Only. Not for Human Consumption. Not a drug, food, or cosmetic.
Article reflects published preclinical and in-vitro literature. Additional citations available on request to research@peptitan.eu.